Incyte treats first patient in its Phase 3 ruxolitinib clinical trial
Category: #health  By Mateen Dalal  Date: 2019-09-27
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Incyte treats first patient in its Phase 3 ruxolitinib clinical trial

Vitiligo is a common disease that causes the patient to lose skin color in random blotches. The disease can affect any body part, even affecting the inside of the patient’s mouth and hair. There are some treatments that help in restoring the color of the affected skin, however it does not treat continued loss in skin color over the affected skin. Various pharmaceutical is still developing effective therapies, so as to completely eliminate this disorder.

One such stride was made recently by Incyte Corp, an American pharmaceutical company, when it announced that it has treated its first patient in Phase 3 TRuE-V clinical study program assessing the efficacy and safety of ruxolitinib cream as monotherapy for adult and adolescent patients suffering from vitiligo.

Commenting on the development, Jim Lee, M.D., Ph.D., Head of Inflammation and Autoimmunity Group and Group Vice President, Incyte, said that vitiligo is a challenging, life-altering disease that if further complicated by the fact that there are no effective treatment options currently available in the market.

Lee further added that the launch of global Phase 3 TRuE-V clinical study program marks a major milestone for the company as it seeks to offer an effective treatment option that provides substantial improvements for patients suffering from vitiligo.

This announcement follows the company’s earlier announcement where it reported positive results from its Phase 2 ruxolitinib cream clinical trial.

Earlier in June, the company announced its 24-week results from the double-blind, randomized, vehicle-controlled, dose-ranging Phase 2 trial assessing the efficacy of ruxolitinib cream, in adult patients between the age of 18 to 75 with vitiligo.

Reportedly, the trial achieved its primary endpoint, establishing that more patients treated with the cream for 24 weeks attained a ≥50% improvement from the baseline of facial vitiligo.

Steven Stein, M.D., Chief Medical Officer, Incyte, said that the promising 24-week data shown at the World Congress of Dermatology reinforces the ability of the cream to provide an effective treatment option for people suffering from the severe autoimmune disease.

According to reports, any further details pertaining to the treatment of patient under the Phase 3 trial have not been unveiled yet.

 Source Credit: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-first-patient-treated-phase-3-clinical-trial-3

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-results-phase-2-study-ruxolitinib

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...